RxDoctor Payments Data

Marielba Agosto, MD

Endocrinology, Diabetes & Metabolism · Cayey, PRNPI 1902078157

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $19,122 of the $28,471 with a category attached, or 67.2%. Sanofi-aventis U.S. LLC accounts for 65.7% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $11,494 and has fallen 89.8% since, to $1,177 in 2025. Among endocrinology, diabetes & metabolism clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$28,471in general payments, 2019–2025

Across 151 payments — averaging $188.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$19K
  • Boehringer Ingelheim$3K
  • Merck$2K
  • Medtronic$1K
  • Amgen$842
  • AstraZeneca$770
  • plus $1K from 11 others

What the payments were for

  • Consulting fees$2,0757%
  • Speaking & faculty fees$19,12267%
  • Travel & lodging$8323%
  • Food & beverage$6,35622%
  • Education$870%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,471 in reported general payments places this provider in the 90th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

See all endocrinology, diabetes & metabolism providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$8,387
Medicare patients
31
Services billed
82

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trijardy XrEmpaglifloz/Linaglip/Metformin413$429,274
OzempicSemaglutide219$274,685
TrulicityDulaglutide175$273,350
Synjardy XrEmpagliflozin/Metformin Hcl187$207,786
FarxigaDapagliflozin Propanediol152$170,504
JardianceEmpagliflozin124$149,466
Xigduo XrDapaglifloz Propaned/Metformin111$139,377
ProliaDenosumab73$128,357
Janumet XrSitagliptin Phos/Metformin Hcl110$121,676
SynthroidLevothyroxine Sodium1,209$111,361
Soliqua 100-33Insulin Glargine/Lixisenatide74$79,755
TymlosAbaloparatide28$74,888
GlyxambiEmpagliflozin/Linagliptin75$74,227
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog46$45,825
JanumetSitagliptin Phos/Metformin Hcl28$41,574

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimTrijardy Xr, Synjardy Xr, Jardiance, Glyxambi, Synjardy$3,177$924,859859 claims
Novo NordiskOzempic, Novolog$232$284,450240 claims
MerckJanumet Xr, Janumet, Januvia$2,422$191,155159 claims
AstraZenecaFarxiga$770$170,504152 claims
AmgenProlia$842$128,35773 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$18,711$117,396248 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

Other endocrinology, diabetes & metabolism in Cayey

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →